Drug Trial Radar · NCT00004984
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
Last checked: Nov 20, 2026Latest source record: Apr 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
711
Actual
Start
Feb 1994
Primary completion
Jun 2003
Study completion Jun 2003
Sponsor
- Sponsor type
- NIH
- Collaborators
- National Center for Research Resources (NCRR); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Minority Health and Health Disparities (NIMHD); Office of Research on Women's Health (ORWH)
- First posted
- Mar 14, 2000
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Diabetes Prevention Trial of Type 1 (DPT-1) was a multicenter randomized, controlled clinical trial designed to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of insulin in individuals determined to be at risk for the disease. Subjects were recruited from study clinics and through media campaigns.First-degree relatives, 3 to 45 years of age, and second-degree relatives, 3 to 20 years of age, of patients with diabetes were screened for islet-cell antibodies. Those individuals found to be at high risk of diabetes were randomized to receive either close observation or low-dose parenteral insulin. Those individuals found to be at intermediate risk of diabetes are randomized to receive insulin orally or to receive placebo. Patients were followed for up to six years.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Parenteral InsulinDrug
Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
Close ObservationOther
Study visits every 6 months including an oral glucose tolerance test
Oral InsulinDrug
Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
PlaceboDrug
Placebo for oral insulin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Type 1 Diabetes Per YearTime frame: Glucose tolerance is measured every 6 months for up to 6 years
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Childrens Hospital of Los Angeles, Division of Endocrinology
Los Angeles, California
University of California-San Francisco, Milberry Union East RM 405, 500 Parnassus Ave Box 0136
San Francisco, California
Stanford University
Stanford, California
University of Colorado Barbara Davis Center for Childhood Diabetes
Denver, Colorado
University of Florida Diabetes Research Center
Gainesville, Florida
DPT-1 Operations Coordinating Center
Miami, Florida
University of Miami School of Medicine, Jackson Medical Tower
Miami, Florida
Indiana University, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr, Ste 5960
Indianapolis, Indiana
Joslin Diabetes Center
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave
New York, New York
Children's Hospital of Pittsburgh, Dept/Pediatric Endocrinology, 3705 5th Ave
Pittsburgh, Pennsylvania
University of Texas, Children's Medical Center, 6300 Harry Hines Ste 1200
Dallas, Texas
Virginia Mason Research Center, 1201 Ninth Avenue
Seattle, Washington
Hospital for Sick Children, Division of Endocrinology, 555 University Ave, Rm 5110
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.